Aprogen Biologics Statistics

Total Valuation

Aprogen Biologics has a market cap or net worth of KRW 132.57 billion. The enterprise value is 178.57 billion.

Market Cap	132.57B
Enterprise Value	178.57B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Aprogen Biologics has 197.57 million shares outstanding. The number of shares has increased by 62.18% in one year.

Current Share Class	n/a
Shares Outstanding	197.57M
Shares Change (YoY)	+62.18%
Shares Change (QoQ)	+148.49%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	0.16%
Float	84.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.91
PB Ratio	0.30
P/TBV Ratio	0.31
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.10, with an EV/FCF ratio of -4.11.

EV / Earnings	-1.26
EV / Sales	2.62
EV / EBITDA	5.10
EV / EBIT	11.33
EV / FCF	-4.11

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.25.

Current Ratio	1.15
Quick Ratio	0.57
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-2.46
Interest Coverage	-17.68

Financial Efficiency

Return on equity (ROE) is -30.31% and return on invested capital (ROIC) is -7.85%.

Return on Equity (ROE)	-30.31%
Return on Assets (ROA)	-6.99%
Return on Capital (ROIC)	-7.85%
Revenue Per Employee	180.46M
Profits Per Employee	-376.06M
Employee Count	377
Asset Turnover	0.10
Inventory Turnover	1.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.20% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-67.20%
50-Day Moving Average	780.12
200-Day Moving Average	1,111.15
Relative Strength Index (RSI)	37.42
Average Volume (20 Days)	789,622

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aprogen Biologics had revenue of KRW 68.03 billion and -141.77 billion in losses. Loss per share was -1,529.21.

Revenue	68.03B
Gross Profit	-3.63B
Operating Income	-76.92B
Pretax Income	-150.05B
Net Income	-141.77B
EBITDA	-57.70B
EBIT	-76.92B
Loss Per Share	-1,529.21

Full Income Statement

Balance Sheet

The company has 60.88 billion in cash and 106.88 billion in debt, giving a net cash position of -46.00 billion or -232.82 per share.

Cash & Cash Equivalents	60.88B
Total Debt	106.88B
Net Cash	-46.00B
Net Cash Per Share	-232.82
Equity (Book Value)	435.62B
Book Value Per Share	2,204.84
Working Capital	19.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -28.31 billion and capital expenditures -15.16 billion, giving a free cash flow of -43.47 billion.

Operating Cash Flow	-28.31B
Capital Expenditures	-15.16B
Free Cash Flow	-43.47B
FCF Per Share	-220.02

Full Cash Flow Statement

Margins

Gross margin is -5.33%, with operating and profit margins of -113.07% and -208.39%.

Gross Margin	-5.33%
Operating Margin	-113.07%
Pretax Margin	-220.55%
Profit Margin	-208.39%
EBITDA Margin	-84.81%
EBIT Margin	-113.07%
FCF Margin	n/a

Dividends & Yields

Aprogen Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.18%
Shareholder Yield	-62.18%
Earnings Yield	-227.90%
FCF Yield	-32.79%

Stock Splits

The last stock split was on March 27, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 27, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Aprogen Biologics has an Altman Z-Score of -0.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.2
Piotroski F-Score	n/a